Literature DB >> 27371639

ADDENDUM: T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.

Eugenia Zah, Meng-Yin Lin, Anne Silva-Benedict, Michael C Jensen, Yvonne Y Chen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27371639      PMCID： PMC4943870          DOI： 10.1158/2326-6066.CIR-16-0108

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN： 2326-6066            Impact factor:   11.151


× No keyword cloud information.
  4 in total

1.  T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.

Authors:  Eugenia Zah; Meng-Yin Lin; Anne Silva-Benedict; Michael C Jensen; Yvonne Y Chen
Journal:  Cancer Immunol Res       Date:  2016-04-08       Impact factor: 11.151

2.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Authors:  Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall
Journal:  Lancet       Date:  2014-10-13       Impact factor: 79.321

3.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

4.  The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.

Authors:  Michael Hudecek; Daniel Sommermeyer; Paula L Kosasih; Anne Silva-Benedict; Lingfeng Liu; Christoph Rader; Michael C Jensen; Stanley R Riddell
Journal:  Cancer Immunol Res       Date:  2014-09-11       Impact factor: 11.151
  4 in total
  6 in total

Review 1.  Therapeutic T cell engineering.

Authors:  Michel Sadelain; Isabelle Rivière; Stanley Riddell
Journal:  Nature       Date:  2017-05-24       Impact factor: 49.962

Review 2.  CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV.

Authors:  Gloria B Kim; Kristen Hege; James L Riley
Journal:  Front Immunol       Date:  2019-09-27       Impact factor: 7.561

Review 3.  Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies.

Authors:  Zhenling Guo; Sanfang Tu; Siyao Yu; Liufang Wu; Wanying Pan; Ning Chang; Xuan Zhou; Chaoyang Song; Yuhua Li; Yanjie He
Journal:  Cancer Sci       Date:  2021-02-21       Impact factor: 6.716

4.  Nanobody Based Dual Specific CARs.

Authors:  Stijn De Munter; Joline Ingels; Glenn Goetgeluk; Sarah Bonte; Melissa Pille; Karin Weening; Tessa Kerre; Hinrich Abken; Bart Vandekerckhove
Journal:  Int J Mol Sci       Date:  2018-01-30       Impact factor: 5.923

5.  Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly.

Authors:  Stijn De Munter; Alexander Van Parys; Layla Bral; Joline Ingels; Glenn Goetgeluk; Sarah Bonte; Melissa Pille; Lore Billiet; Karin Weening; Annick Verhee; Jose Van der Heyden; Tom Taghon; Georges Leclercq; Tessa Kerre; Jan Tavernier; Bart Vandekerckhove
Journal:  Int J Mol Sci       Date:  2020-01-30       Impact factor: 5.923

6.  Optimization of GPC3-specific chimeric antigen receptor structure and its effect on killing hepatocellular carcinoma cells.

Authors:  Jianfeng Zhao; Lijuan Lin; Yihua Luo; Qinghe Cai; Xiaojie Jiang; Changxi Liao; Huimin Wei
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.